Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB012 in Active Ulcerative Colitis
NCT02129439Phase 2Completed
- Sponsor
- sterna biologicals
- Start
- Apr 2014
- Primary completion
- Jun 2017
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ulcerative colitis (UC) comparing SB012 with Placebo (2 arms). Primary endpoint: Total Mayo Score at 4 weeks. Started Apr 2014; status: completed.
02
Drugs
SB012
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02129439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02129439.